Can PepFold design peptides for rs1799853?

Yes. PepFold accepts rs1799853 as input, annotates it via ClinVar, maps it to the CYP2C9 protein via UniProt, generates peptide candidates targeting affected functional domains, predicts their 3D structures with ESMFold, and produces a scored report with Fmoc-SPPS synthesis protocols.

SNP Database

rs1799853 — CYP2C9 CYP2C9*2 (Arg144Cys)

Q: What gene is rs1799853 in?

rs1799853 is a variant in the CYP2C9 (Cytochrome P450 2C9) gene located on chromosome 10q23.33. Metabolizes ~15% of clinical drugs including warfarin (S-enantiomer), NSAIDs, sulfonylureas, and losartan. CYP2C9 genotype is part of FDA warfarin dosing guidelines.

Q: What is the clinical significance of rs1799853?

rs1799853 is classified as "Drug response" in ClinVar. The Arg144Cys substitution is near the CYP2C9 active site and reduces catalytic efficiency for S-warfarin hydroxylation. Carriers clear warfarin more slowly, requiring lower doses to avoid bleeding complications.

Drug response · ~12% Caucasians

rs1799853 defines the CYP2C9*2 allele, which reduces warfarin metabolism by ~30%. Combined with VKORC1 variants, it is part of FDA-recommended pharmacogenomic testing for warfarin dosing.

Molecular Mechanism

The Arg144Cys substitution is near the CYP2C9 active site and reduces catalytic efficiency for S-warfarin hydroxylation. Carriers clear warfarin more slowly, requiring lower doses to avoid bleeding complications.

Peptide Therapeutic Relevance

Peptide anticoagulants could offer more predictable pharmacokinetics than warfarin, independent of CYP2C9 genotype. PepFold generates candidates targeting the coagulation cascade with built-in metabolism resistance.

Gene: CYP2C9 (Cytochrome P450 2C9)

Metabolizes ~15% of clinical drugs including warfarin (S-enantiomer), NSAIDs, sulfonylureas, and losartan. CYP2C9 genotype is part of FDA warfarin dosing guidelines.

Chromosome 10q23.33

Full CYP2C9 gene profile →

Condition: Warfarin Sensitivity

Genetic variation in VKORC1 and CYP2C9 determines warfarin dose requirements. FDA recommends pharmacogenomic testing, and genotype-guided dosing reduces bleeding events by 30%. It is the most established pharmacogenomic application in clinical practice.

Prevalence: ~2 million US patients on warfarin, ~30% experience dosing complications

Full Warfarin Sensitivity profile →

Related Variants

rs1057910CYP2C9 — CYP2C9*3 (Ile359Leu)rs9923231VKORC1 — -1639G>A (promoter)

Analyze rs1799853 with PepFold

Submit rs1799853 and get ranked peptide candidates with 3D structures and synthesis protocols in under 2 minutes.

Try Analysis View Pricing